July 10, 2005 -- Last week, biotech put in a rip-roaring performance. In a holiday-shortened span comprising just 4 trading days, the Centient Biotech 200 managed to climb 4.41%. Ending at 3511.33, after rising 148 points, the CBT 200 had the highest weekly closing price of the year. If 3500 on the CBT 200 was Mt. Everest, then Amgen was the Sherpa. The biotech behemoth was tenth on the list of percentage winners for the week, rising 13.6%, with a gain in market capitalization over $11 billion. We look at significant companies - Senomyx, Momenta and Eyetech - that have been trading for more than 12 months and thus migrated from the list of recent IPOs into the CBT 200, plus we list the most important earnings announcements for biotech companies in the coming week...
